NextCure stock fell 3.79 percent as court review loomed
Published on 09/28/2026 at 23:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
NextCure stock fell 3.79 percent to USD 5.08 at the September 25, 2026 close on Nasdaq, leaving the biotechnology company valued at USD 23.3 million. On September 25, 2026, StockTitan reported that NextCure had asked the Delaware Court of Chancery to validate its 1-for-12 reverse split.
Court review sets a key date
The hearing is scheduled for 3:00 p.m. ET on November 6, 2026. Stockholders may submit written positions by October 27, 2026, creating a defined legal timetable around the companys capital structure and proposed business combination with Avere Therapeutics.
The petition concerns a split that became effective on July 14, 2025. The filing states that 18,166,577 votes supported the amendment, compared with 2,028,946 against, equal to 89.92 percent of votes cast and 64.76 percent of outstanding shares entitled to vote.
Loss narrows, cash remains central
For the three months ended June 30, 2026, NextCure reported a net loss of USD 14.892 million, down from USD 26.808 million in the prior-year quarter, according to StockTitan. Basic and diluted loss per share was USD 2.80, compared with USD 11.29 a year earlier.
Cash, cash equivalents and marketable securities totaled USD 20.088 million on June 30, 2026, versus USD 41.818 million on December 31, 2025. Research and development expense fell to USD 7.425 million from USD 24.091 million, while the company also recorded a USD 5.077 million asset impairment charge.
NextCure stock stays near its yearly low
At USD 5.08, the shares were USD 3.53 above the 52-week low of USD 1.55 and USD 10.66 below the 52-week high of USD 15.74 on September 25, 2026. Volume was 71,790 shares, while the legal process adds a concrete event risk to a company still reporting quarterly losses.
NextCure stock data
- Company: NextCure, Inc.
- Ticker: NXTC
- Trading venue: Nasdaq Global Select Market
- Price (as of September 25, 2026): Closing price USD 5.08
- Market capitalization: USD 23.3 million (as of September 25, 2026)
- 52-week range: USD 1.55-15.74 (as of September 25, 2026)
- Sector / Industry: Healthcare / Biotechnology
